Functional Analysis of the p53 Pathway in Neuroblastoma Cells Using the Small-Molecule MDM2 Antagonist Nutlin-3

被引:62
作者
Van Maerken, Tom [1 ,2 ]
Rihani, Ali [1 ]
Dreidax, Daniel [4 ]
De Clercq, Sarah [3 ]
Yigit, Nurten [1 ]
Marine, Jean-Christophe [3 ]
Westermann, Frank [4 ]
De Paepe, Anne [1 ]
Vandesompele, Jo [1 ]
Speleman, Frank [1 ]
机构
[1] Ghent Univ Hosp, Ctr Genet Med, B-9000 Ghent, Belgium
[2] Ghent Univ Hosp, Dept Clin Chem Microbiol & Immunol, B-9000 Ghent, Belgium
[3] VIB UGent, Lab Mol Canc Biol, Ghent, Belgium
[4] German Canc Res Ctr, Dept Tumor Genet, D-6900 Heidelberg, Germany
关键词
WILD-TYPE P53; ARF TUMOR-SUPPRESSOR; P53/MDM2/P14(ARF) PATHWAY; CYTOPLASMIC SEQUESTRATION; SENSITIZES NEUROBLASTOMA; INDUCED APOPTOSIS; GENE-MUTATIONS; LINES; FREQUENCY; NUCLEAR;
D O I
10.1158/1535-7163.MCT-10-1090
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Suppression of p53 activity is essential for proliferation and survival of tumor cells. A direct p53-activating compound, nutlin-3, was used in this study, together with p53 mutation analysis, to characterize p53 pathway defects in a set of 34 human neuroblastoma cell lines. We identified 9 cell lines (26%) with a p53 loss-of-function mutation, including 6 missense mutations, 1 nonsense mutation, 1 in-frame deletion, and 1 homozygous deletion of the 30 end of the p53 gene. Sensitivity to nutlin-3 was highly predictive of absence of p53 mutation. Signaling pathways downstream of p53 were functionally intact in 23 of 25 cell lines with wild-type p53. Knockdown and overexpression experiments revealed a potentiating effect of p14(ARF) expression on the response of neuroblastoma cells to nutlin-3. Our findings shed light on the spectrum of p53 pathway lesions in neuroblastoma cells, indicate that defects in effector molecules downstream of p53 are remarkably rare in neuroblastoma, and identify p14(ARF) as a determinant of the outcome of the response to MDM2 inhibition. These insights may prove useful for the clinical translation of evolving strategies aimed at p53 reactivation and for the development of new therapeutic approaches. Mol Cancer Ther; 10(6); 983-93. (C)2011 AACR.
引用
收藏
页码:983 / 993
页数:11
相关论文
共 46 条
[1]   MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death [J].
Barbieri, Eveline ;
Mehta, Parth ;
Chen, Zaowen ;
Zhang, Linna ;
Slack, Andrew ;
Berg, Stacey ;
Shohet, Jason M. .
MOLECULAR CANCER THERAPEUTICS, 2006, 5 (09) :2358-2365
[2]   Hyperubiquitylation of wild-type p53 contributes to cytoplasmic sequestration in neuroblastoma [J].
Becker, K. ;
Marchenko, N. D. ;
Maurice, M. ;
Moll, U. M. .
CELL DEATH AND DIFFERENTIATION, 2007, 14 (07) :1350-1360
[3]  
BIEDLER JL, 1978, CANCER RES, V38, P3751
[4]   Awakening guardian angels: drugging the p53 pathway [J].
Brown, Christopher J. ;
Lain, Sonia ;
Verma, Chandra S. ;
Fersht, Alan R. ;
Lane, David P. .
NATURE REVIEWS CANCER, 2009, 9 (12) :862-873
[5]   Increased frequency of aberrations in the p53/MDM2/p14ARF pathway in neuroblastoma cell lines established at relapse [J].
Carr, J ;
Bell, E ;
Pearson, ADJ ;
Kees, UR ;
Beris, H ;
Lunec, J ;
Tweddle, DA .
CANCER RESEARCH, 2006, 66 (04) :2138-2145
[6]   High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma [J].
Carr-Wilkinson, Jane ;
O'Toole, Kieran ;
Wood, Katrina M. ;
Challen, Christine C. ;
Baker, Angela G. ;
Board, Julian R. ;
Evans, Laura ;
Cole, Michael ;
Cheung, Nai-Kong V. ;
Boos, Joachim ;
Koehler, Gabriele ;
Leuschner, Ivo ;
Pearson, Andrew D. J. ;
Lunec, John ;
Tweddle, Deborah A. .
CLINICAL CANCER RESEARCH, 2010, 16 (04) :1108-1118
[7]   NO TP53 MUTATIONS IN NEUROBLASTOMAS DETECTED BY PCR-SSCP ANALYSIS [J].
CASTRESANA, JS ;
BELLO, ML ;
REY, JA ;
NEBREDA, P ;
QUEIZAN, A ;
GARCIAMIGUEL, P ;
PESTANA, A .
GENES CHROMOSOMES & CANCER, 1994, 10 (02) :136-138
[8]   ARF-BP1/mule is a critical mediator of the ARF tumor suppressor [J].
Chen, DL ;
Kon, N ;
Li, MY ;
Zhang, WZ ;
Qin, J ;
Gu, W .
CELL, 2005, 121 (07) :1071-1083
[9]   p53 is nuclear and functional in both undifferentiated and differentiated neuroblastoma [J].
Chen, Lindi ;
Malcolm, Archie J. ;
Wood, Katrina M. ;
Cole, Michael ;
Variend, Sadick ;
Cullinane, Catherine ;
Pearson, Andrew D. J. ;
Lunec, John ;
Tweddle, Deborah A. .
CELL CYCLE, 2007, 6 (21) :2685-2696
[10]  
DAVIDOFF AM, 1992, ONCOGENE, V7, P127